Cargando…
Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
OBJECTIVE: To evaluate the prevalence of infections, prevalence of hospitalisation due to infections, the vaccination status and perceived screening of infections prior to the start of biologic disease modifying antirheumatic drugs (bDMARDs) of a patient cohort with chronic inflammatory rheumatic di...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039255/ https://www.ncbi.nlm.nih.gov/pubmed/33832974 http://dx.doi.org/10.1136/rmdopen-2020-001499 |
_version_ | 1783677549627310080 |
---|---|
author | Kiltz, Uta Celik, Aylin Tsiami, Styliani Buehring, Bjoern Baraliakos, Xenofon Andreica, Ioana Kiefer, David Braun, Juergen |
author_facet | Kiltz, Uta Celik, Aylin Tsiami, Styliani Buehring, Bjoern Baraliakos, Xenofon Andreica, Ioana Kiefer, David Braun, Juergen |
author_sort | Kiltz, Uta |
collection | PubMed |
description | OBJECTIVE: To evaluate the prevalence of infections, prevalence of hospitalisation due to infections, the vaccination status and perceived screening of infections prior to the start of biologic disease modifying antirheumatic drugs (bDMARDs) of a patient cohort with chronic inflammatory rheumatic diseases (CIRD). METHODS: Consecutive CIRD patients reporting to our specialised centre were prospectively included (n=975) in this cross-sectional study. Data on comorbidities including infections, treatment, vaccination status, screening for latent tuberculosis infection (LTBI) and hepatitis B (HepB) were collected. Antibodies against measles and HepB were measured by ELISA. The vaccination status was assessed by a predefined vaccination score (0–26) categorising patients into four immunisation states: low (0–6), moderate (7–13), good (14–20), high (21–26). RESULTS: All patients on bDMARDs (n=499) were screened for LTBI, and 469 for HepB (94%). All LTBI patients (n=16) received isoniazid (3.2%) and 16 chronic HepB patients received lamivudine (3.4%). Protective measles specific IgG-antibodies were found in 901 patients (92.4%). Although 629 patients were educated about vaccination strategies (64.5%), only 540 showed a vaccination card (55.4%). Only 49% of patients had undergone pneumococcal vaccination and less than 30% were protected against HepB and influenza, while 7.6% have not protective antibody titres against measles. No patient met the German national vaccination recommendations requiring a complete documentation of vaccines. The mean vaccination score was 13.3±4.2 with 5.7% of patients having a low, 43.9% a moderate, 47.0% a good and 3.3% a high score. CONCLUSIONS: The majority of CIRD patients are n0t sufficiently vaccinated against pneumococci, HepB, influenza and measles. Although CIRD patients and general practitioners regularly receive professional information about the need of vaccination, vaccination rates were low to moderate. Interdisciplinary quality projects should be planned to change that inacceptable result. |
format | Online Article Text |
id | pubmed-8039255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80392552021-04-26 Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study Kiltz, Uta Celik, Aylin Tsiami, Styliani Buehring, Bjoern Baraliakos, Xenofon Andreica, Ioana Kiefer, David Braun, Juergen RMD Open Infections OBJECTIVE: To evaluate the prevalence of infections, prevalence of hospitalisation due to infections, the vaccination status and perceived screening of infections prior to the start of biologic disease modifying antirheumatic drugs (bDMARDs) of a patient cohort with chronic inflammatory rheumatic diseases (CIRD). METHODS: Consecutive CIRD patients reporting to our specialised centre were prospectively included (n=975) in this cross-sectional study. Data on comorbidities including infections, treatment, vaccination status, screening for latent tuberculosis infection (LTBI) and hepatitis B (HepB) were collected. Antibodies against measles and HepB were measured by ELISA. The vaccination status was assessed by a predefined vaccination score (0–26) categorising patients into four immunisation states: low (0–6), moderate (7–13), good (14–20), high (21–26). RESULTS: All patients on bDMARDs (n=499) were screened for LTBI, and 469 for HepB (94%). All LTBI patients (n=16) received isoniazid (3.2%) and 16 chronic HepB patients received lamivudine (3.4%). Protective measles specific IgG-antibodies were found in 901 patients (92.4%). Although 629 patients were educated about vaccination strategies (64.5%), only 540 showed a vaccination card (55.4%). Only 49% of patients had undergone pneumococcal vaccination and less than 30% were protected against HepB and influenza, while 7.6% have not protective antibody titres against measles. No patient met the German national vaccination recommendations requiring a complete documentation of vaccines. The mean vaccination score was 13.3±4.2 with 5.7% of patients having a low, 43.9% a moderate, 47.0% a good and 3.3% a high score. CONCLUSIONS: The majority of CIRD patients are n0t sufficiently vaccinated against pneumococci, HepB, influenza and measles. Although CIRD patients and general practitioners regularly receive professional information about the need of vaccination, vaccination rates were low to moderate. Interdisciplinary quality projects should be planned to change that inacceptable result. BMJ Publishing Group 2021-04-08 /pmc/articles/PMC8039255/ /pubmed/33832974 http://dx.doi.org/10.1136/rmdopen-2020-001499 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infections Kiltz, Uta Celik, Aylin Tsiami, Styliani Buehring, Bjoern Baraliakos, Xenofon Andreica, Ioana Kiefer, David Braun, Juergen Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title | Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title_full | Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title_fullStr | Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title_full_unstemmed | Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title_short | Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study |
title_sort | are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? a cross-sectional cohort study |
topic | Infections |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039255/ https://www.ncbi.nlm.nih.gov/pubmed/33832974 http://dx.doi.org/10.1136/rmdopen-2020-001499 |
work_keys_str_mv | AT kiltzuta arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT celikaylin arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT tsiamistyliani arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT buehringbjoern arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT baraliakosxenofon arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT andreicaioana arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT kieferdavid arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy AT braunjuergen arepatientswithrheumaticdiseasesonimmunosuppressivetherapiesprotectedagainstpreventableinfectionsacrosssectionalcohortstudy |